Ivonescimab and ADG126 for advanced MSS colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of drugs (ivonescimab and ADG126) given alone or with standard chemotherapy pills and IV therapy for people with advanced or metastatic colorectal cancer that is MSS (a subtype). The goal is to see if this approach works better for patients who have already tried certain chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic colorectal cancer that is MSS (a specific type that doesn't have high instability).
- You have not had an immunotherapy drug that targets PD-1 or PD-L1 before.
- You have at least one tumor that can be measured on scans (like CT or MRI).
- Your blood counts (like neutrophils, platelets, and hemoglobin) are within a healthy range.
- Your liver, kidney, and blood clotting tests are at acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial tests a new combination of drugs (Ivosidenib/AK112, CapeOX chemotherapy, and radiation) for people with advanced colorectal cancer that has spread and cannot be removed with surgery. It is for those whose tumors are MSS (microsatellite stable) type and who have not received recent chemotherapy.
This trial tests whether combining two drugs—bevacizumab and adebrelimab—can help people with a specific type of colorectal cancer that has spread and is MSS-type. It's for patients who have already had standard chemotherapy and have tumors that show certain genetic features.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Hear when a new Metastatic Microsatellite Stable Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.